StockData
Eloxx Pharmaceuticals, Inc. logo

Eloxx Pharmaceuticals, Inc. (ELOX) stock

ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$12.75−0.40 (-3.04%)

Close on Nov 16, 2026Market cap $86.56MP/E –Yield –

Eloxx Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Eloxx Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2016 was -$11.10M. For fiscal 2016 it was -$11.10M. The highest annual figure on record is -$4.36M in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2016Jun 30, 2016-$11.10M–
FY2015Jun 30, 2015-$17.90M–
FY2014Jun 30, 2014-$8.80M–
FY2013Jun 30, 2013-$4.36M–
FY2012Jun 30, 2012-$5.15M–
FY2011Jun 30, 2011-$7.78M–
FY2010Jun 30, 2010-$4.72M–

Quarterly ebitda

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2016CQ2 2016Jun 30, 2016-$1.38M–
Q3 FY2016CQ1 2016Mar 31, 2016-$4.87M–
Q2 FY2016CQ4 2015Dec 31, 2015-$3.73M–
Q1 FY2016CQ3 2015Sep 30, 2015-$1.12M–
Q4 FY2015CQ2 2015Jun 30, 2015-$880.91K–
Q3 FY2015CQ1 2015Mar 31, 2015-$1.19M–
Q2 FY2015CQ4 2014Dec 31, 2014-$10.71M–
Q1 FY2015CQ3 2014Sep 30, 2014-$5.13M–
Q4 FY2014CQ2 2014Jun 30, 2014-$3.57M–
Q3 FY2014CQ1 2014Mar 31, 2014-$2.04M–

More Eloxx Pharmaceuticals figures

See a number that looks wrong?